In the peer-reviewed study, Crescel’s biobotanical formula achieved a 54% reduction in facial redness, compared to 23% for the current prescription standard. Inflammatory lesions saw a 74% improvement, starkly contrasting with the 17% reduction observed in the control group. These results suggest a potential shift toward non-pharmaceutical interventions for a condition that currently affects roughly 400 million people globally.

Peter J. Passalacqua, Jr., CEO of Crescel, noted that the data validates years of development aimed at providing effective alternatives to high-cost treatments. Dr. Roberta Shapiro, the company’s Chief Medical Officer and an Assistant Clinical Professor at Columbia University Medical Center, described the findings as a notable advancement, citing the cream’s healing capabilities and safety profile. The company intends to leverage these clinical outcomes to advocate for broader access to affordable, non-prescription-based skin health solutions.